BAC vs PFE: Which Is the Better Buy?
Side-by-side comparison of Bank of America Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-22.
Bank of America Corporation · Financial Services
$57.96
+15.7% upside to fair value
Med Conviction
Grade B
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
BAC has more upside to fair value
(+15.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
BAC |
PFE |
| Current Price |
$57.96 |
$27.64 |
| Fair Value Estimate |
$67.08 |
$30.94 |
| Upside to Fair Value |
+15.7%
|
+12.0%
|
| Market Cap |
$411.3B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.4x
|
17.4x
|
| Price / Sales |
2.1x
|
2.5x
|
| Price / FCF |
4.4x
|
14.3x
|
| Revenue Growth YoY |
+5.8%
|
+2.6%
|
| Gross Margin |
59.3%
|
71.3%
|
| Operating Margin |
22.5%
|
25.1%
|
| Return on Equity |
11.1%
|
4.9%
|
| Dividend Yield |
2.0% |
6.22% |
| FCF Yield |
22.88%
|
6.97%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Bank of America Corporation is a diversified U.S. money-center bank operating through Consumer Banking, Global Wealth & Investment Management, Global Banking, and Global Markets, serving roughly 67 million consumer and small business clients through about 4,200 retail financial centers and 16,000 ATMs as of the last detailed disclosure. The franchise quality is solid but not exceptional: TTM net …
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
BAC |
PFE |
| Zone Low |
$50.31 |
$23.21 |
| Zone High |
$57.02 |
$26.30 |
| In Buy Zone? |
No
|
No
|